汉族COPD患者使用不同干粉吸入剂的疗效差异——基于药物基因组学比较

Difference in the Clinical Efficacy of Chinese COPD Patients Using Different Dry Powder Inhalers——A Comparison Based on Pharmacogenomics

基于药物基因组学比较慢性阻塞性肺疾病(COPD)患者使用3种干粉吸入剂(DPI)的疗效。收集莆田地区汉族COPD患者COPD评估测试评分(CAT)及肺功能数据,从ADRB2基因多态性比较3者的疗效差异。结果:共104例患者;AA型35例,使用噻托溴胺(TIO)改善明显(P<0.05);GG型24例,TIO的CAT变化小于布地奈德福莫特罗(BUD/FM),FEV1%改善较差(P<0.05),FEV1/FVC则无显著差异(P>0.05);GA型45例,3者无显著差异(P>0.05)。根据结果推荐COPD患者:AA型选用TIO,GG型选用BUD/FM,GA型3种DPI均可选用。

The clinical efficacy of 3 different dry powder inhalers in COPD patients based on pharmacogenomicswas compared. The score of COPD assessment test and lung function test index of COPD patients in Putian City werecollected, and then the data were analyzed based on ADRB2 gene polymorphism. The results showed that the 104COPD patients involved, with 35 cases in AA genotype. They had significant advantages treated with Tiotropium（P〈0.05）. 24 patients in GG genotype treated with Tiotropium which were worse than Budesonide/Formoterol in differentCAT scores, and worst in FEV1%（P〈0.05）. But it had no difference in FEV1/FVC（P〉0.05）. And3 dry powderinhalers had not significant difference among GA genotype patients（P〉0.05）. It draw the conclusion that AA genotypeCOPD patients could be treated by Tiotropium bromide; Budesonide/Formoterol might be applied in GG genotypepatients, and GA genotype patients could use 3 dry powder inhalers.